Lipid nanoparticle suitable for RPE cell transfection and use thereof

By developing lipid nanoparticles suitable for RPE cells, using the combination of steroids, cationic, auxiliary lipids and pegylated lipids, efficient nucleic acid delivery and gene editing are achieved, solving the inefficient delivery efficiency in the prior art and The problem of immune response has significantly improved the therapeutic effect of RPE cells.

WO2024234780A1PCT designated stage expired Publication Date: 2024-11-21BASE THERAPEUTICS (SHANGHAI) CO LTD +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/079595
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-18
Filing Date
2024-03-01
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

The existing AAV delivery systems are inefficient in the treatment of ophthalmic diseases and may trigger an immune response, cannot maintain VEGFA neutralization for a long time, and have size limitations on macromolecular gene delivery, making it difficult to effectively target RPE cells.

Method used

A lipid nanoparticle suitable for RPE cell transfection has been developed, containing steroidal lipids, cationic lipids, auxiliary lipids and pegylated lipids, by adjusting their molar ratios and selecting suitable lipid components , form an efficient nucleic acid delivery vector to achieve targeted delivery of RPE cells.

Benefits of technology

The nucleic acid transfection rate was achieved close to 100%, the gene editing efficiency reached 78%, and the base editing efficiency reached 56%, which significantly improved the drug delivery effect against RPE cells, solving the problems of low efficiency and immune response in the existing technology. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024079595_21112024_PF_FP_ABST
    Figure CN2024079595_21112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided are a lipid nanoparticle and lipid nanoparticle-nucleic acid complex suitable for RPE cell transfection. After retinal pigment epithelial cells are transfected with the provided lipid nanoparticle-nucleic acid complex, the transfection rate is close to 100%, the related gene editing efficiency reaches 78%, the related base editing efficiency reaches 56%, and a new technical solution is provided for preparing drugs for treating eye-related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Lipid nanoparticles suitable for RPE cell transfection and their application Technical Field

[0001] This specification relates to the field of biomedicine, and in particular to lipid nanoparticles suitable for RPE cell transfection and their applications. Background Art

[0002] Lipid nanoparticles (Lipid NanoParticles, hereinafter referred to as LNP) delivery system, is based on cholesterol, auxiliary phospholipids, cationic lipids, pegylated lipids as main components, wrapped nucleic acid material to form nanoparticles, thereby a kind of delivery system for gene delivery into cells. Because LNP components are biomimetic from cell membranes, its safety and biocompatibility are good. LNP is currently a very good gene delivery vector clinically, especially for nucleic acid materials such as mRNA with a large number of bases. LNP can efficiently and targetedly carry out gene delivery for different cells through the change in the ratio of its components and the selection of different substances of components.

[0003] Retinal Pigment Epithelium (hereinafter referred to as RPE) is composed of a single layer of retinal pigment epithelial cells (hereinafter referred to as RPE cells), which are located between the retina and the choroid. RPE plays an important role in the normal physiological activities and eye health of the eye. It is not only one of the components of the blood-retinal barrier, but also controls the entry and exit of substances and immune immunity. And the vascular endothelial growth factor (Vascular Endothelial Growth Factor, hereinafter referred to as VEGF) secreted by it, especially VEGFA (a type of VEGF), plays an important role in the growth of blood vessels in the choroid.

[0004] Age-related macular degeneration (AMD) is an acquired retinal degeneration disease that is particularly prevalent in the elderly. It causes severe central vision impairment through the formation of non-neovascular (drusen and RPE abnormalities) and neovascular disorders. The non-neovascular type is atrophic or dry AMD, and the neovascular type is exudative or wet AMD (wAMD). The choroidal neovascularization (CNV) of wAMD infiltrates into the retina, seriously affecting the patient's vision. The growth of CNV is regulated by VEGFA. By reducing the VEGFA content in the eye, the CNV atrophies, thereby controlling the progression of the disease and even curing it.

[0005] RPE cells secrete large amounts of VEGFA near the choroid to maintain normal choroidal vascular growth. In patients with wAMD, VEGFA secretion by RPE cells actually contributes to the development of CNV. Therefore, limiting VEGFA secretion by RPE cells is the most important approach for treating wAMD. Current clinical treatment involves injecting neutralizing antibodies against VEGFA, such as ranibizumab. However, antibodies are metabolized in the body and cannot be maintained long-term, necessitating frequent injections (every 2-3 months). Another approach currently under clinical trial involves using adeno-associated virus (AAV) to deliver mRNA for a VEGFA monoclonal antibody to RPE cells, enabling them to continuously produce neutralizing antibodies. Thus, a single injection can significantly treat wAMD. However, AAV-delivered mRNA is slow to take effect, often requiring weeks or even decades to produce sufficient neutralizing antibodies. Furthermore, AAV administration can trigger an immune response in the body. While this response is relatively mild, in cases where a second AAV injection is required, the immune response can prevent gene delivery after the second injection. AAV is also limited in size and cannot deliver genes larger than 5Kbp.

[0006] Based on this, developing a more efficient and specific RPE cell delivery system is a very important tool for ophthalmic gene therapy, which will greatly promote the development of ophthalmic gene therapy, especially for diseases caused by RPE cells.

[0007] Summary of the Invention

[0008] In order to solve the above problems, the present application provides a lipid nanoparticle-nucleic acid complex for delivering drugs for ophthalmic diseases into RPE cells.

[0009] The present application provides a lipid nanoparticle suitable for RPE cell transfection, wherein the raw materials of the lipid nanoparticle include steroidal lipids, cationic lipids, auxiliary lipids and PEGylated lipids, and the molar ratio of the steroidal lipids, auxiliary lipids, cationic lipids and PEGylated lipids is 37:10:51~51.5:1.5~2; the steroidal lipids are selected from at least one of cholesterol or β-sitosterol, the auxiliary lipids are selected from at least one of cardiolipin or DSPC, the cationic lipids are selected from at least two of SM102, DOTAP or ALC-0315, the PEGylated lipids are selected from at least one of DSPE-PEG-Biotin, DMG-PEG or PEG-folic acid, the cationic lipids include ionizable cationic lipids and permanent cationic lipids, and the molar ratio of the ionizable cationic lipids to the permanent cationic lipids is 25~50:10~25.

[0010] The present application also provides the use of the lipid nanoparticles as a delivery vehicle for nucleic acids.

[0011] The present application also provides a lipid nanoparticle-nucleic acid complex, which comprises a nucleic acid and the above-mentioned lipid nanoparticle, wherein the nucleic acid is loaded in the lipid nanoparticle.

[0012] The present application also provides the use of the above-mentioned lipid nanoparticle-nucleic acid complex for gene editing.

[0013] The present application also provides use of the above-mentioned lipid nanoparticle-nucleic acid complex in the preparation of drugs for treating eye-related diseases.

[0014] The present application also provides a method for delivering nucleic acid to cells, comprising contacting the lipid nanoparticle-nucleic acid complex with the cells.

[0015] The present application also provides a gene editing method, comprising contacting the above-mentioned lipid nanoparticle-nucleic acid complex with cells containing the gene to be edited.

[0016] The present application also provides the use of DSPE-PEG-Biotin in preparing the above-mentioned lipid nanoparticles and the above-mentioned lipid nanoparticle-nucleic acid complexes.

[0017] The beneficial effects brought about by the embodiments of this specification include but are not limited to: (1) lipid nanoparticle-nucleic acid complexes can deliver nucleic acids to cells, making the nucleic acid transfection rate close to 100%; (2) by using lipid nanoparticle-nucleic acid complexes to deliver target nucleic acids to cells, the related gene editing efficiency can reach 78%; (3) by using lipid nanoparticle-nucleic acid complexes to deliver target nucleic acids to cells, the related base editing efficiency can reach 56%. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] The present application will be further described in terms of exemplary embodiments, which will be described in detail with reference to the accompanying drawings. These embodiments are non-limiting, and include:

[0019] FIG1 is a diagram showing components of schemes 1 to 8 according to some embodiments of the present application;

[0020] FIG2 is a diagram showing components of schemes 9 to 16 according to some embodiments of the present application;

[0021] FIG3 is a diagram showing components of solutions 17 to 22 according to some embodiments of the present application;

[0022] FIG4 is a bar graph showing the transfection efficiency of lipid nanoparticle-nucleic acid complexes according to some embodiments of the present application;

[0023] FIG5 is a flow cytometric analysis of the transfection effect of lipid nanoparticle-nucleic acid complexes according to some embodiments of the present application;

[0024] Figure 6 is a bar chart showing the base editing efficiency of lipid nanoparticle-nucleic acid complexes according to some embodiments of the present application;

[0025] Figure 7 is a bar chart showing the gene editing efficiency of lipid nanoparticle-nucleic acid complexes according to some embodiments of the present application. DETAILED DESCRIPTION

[0026] To more clearly illustrate the technical solutions of the embodiments of this specification, the following briefly describes the drawings required for describing the embodiments. Obviously, the drawings described below are merely examples or embodiments of this specification. Those skilled in the art can apply this specification to other similar scenarios based on these drawings without inventive effort. Unless otherwise apparent from the context or otherwise noted, the same reference numerals in the figures represent the same structure or operation.

[0027] As used in this specification and claims, unless the context clearly indicates otherwise, the words "a," "an," "an," and / or "the" do not refer to the singular but also include the plural. Generally speaking, the terms "comprises" and "include" only indicate the inclusion of the steps and elements specifically identified, and these steps and elements do not constitute an exclusive list. A method or apparatus may also include other steps or elements.

[0028] Flowcharts are used throughout this specification to illustrate the operations performed by systems according to embodiments of this specification. It should be understood that preceding or following operations do not necessarily need to be performed in exact order. Instead, the steps may be processed in reverse order or simultaneously. Furthermore, other operations may be added to these processes, or one or more operations may be removed from these processes.

[0029] Due to their inherent properties, such as negative charge and susceptibility to nuclease degradation, nucleic acid drugs cannot effectively penetrate cell membranes and are rapidly degraded in vivo. Therefore, a robust delivery system is required to stably deliver nucleic acids to the target site for efficacy. A common challenge in the development of both mRNA and siRNA is how to effectively deliver them to the target cells. During delivery, considerations also need to be given to preventing rapid clearance, nuclease degradation, and facilitating escape after endocytosis.

[0030] Nucleic acids carry a large number of phosphate groups, giving them a negative charge. To effectively encapsulate them within lipid nanoparticles, a special class of lipids—cationic lipids—is required. Cationic lipids often have a hydrophilic end with an ammonium group, which can bind to hydrogen ions in an acidic environment, resulting in a positive charge. Electrostatic attraction between these two lipids allows nucleic acids to be encapsulated within the lipid nanoparticle. The encapsulated structure becomes hydrophobic due to the outward orientation of the hydrophobic end of the cationic lipid. This allows the addition of a PEG-lipid, a lipid modified with polyethylene glycol (PEG) at one end, commonly used in traditional liposome synthesis. This allows the hydrophobic end of the PEG-lipid to bind to the hydrophobic end of the cationic lipid, while the hydrophilic end of the PEG-lipid (with the PEG attached) faces outward, forming the outer shell of the nucleic acid-lipid nanoparticle. To enhance the stability of the nucleic acid-lipid nanoparticle, an appropriate amount of cholesterol or other ingredients can be added to strengthen the binding between the hydrophobic end of the PEG-lipid and the hydrophobic end of the cationic lipid, ultimately resulting in the final nucleic acid-lipid nanoparticle. When nucleic acid lipid nanoparticles are internalized by cells, the ionizable lipids are pH-sensitive, and the ionizable cationic lipids will ionize in an acidic environment, destroying the endosomal membrane, thereby achieving endosomal escape of lipid nanoparticles (LNPs) and in vivo transfection of nucleic acids.

[0031] Although they are all lipid carriers, the formulation and preparation methods of lipid carriers, as well as the release process of different drug molecules in target tissues or target cells are all different.

[0032] The present application provides a lipid nanoparticle suitable for RPE cell transfection, wherein the raw materials of the lipid nanoparticle include steroidal lipids, cationic lipids, auxiliary lipids and PEGylated lipids, and the molar ratio of the steroidal lipids, auxiliary lipids, cationic lipids and PEGylated lipids is 37:10:51~51.5:1.5~2; the steroidal lipids are selected from at least one of cholesterol or β-sitosterol, the auxiliary lipids are selected from at least one of cardiolipin or DSPC, the cationic lipids are selected from at least two of SM102, DOTAP or ALC-0315, the PEGylated lipids are selected from at least one of DSPE-PEG-Biotin, DMG-PEG or PEG-folic acid, the cationic lipids include ionizable cationic lipids and permanent cationic lipids, and the molar ratio of the ionizable cationic lipids to the permanent cationic lipids is 25~50:10~25.

[0033] The application " lipid nanoparticle " refers to the particle comprising multiple (for example, more than one) lipid molecules physically bound to each other by intermolecular forces.LNP can be, for example, a microsphere (including unilamellar and multilamellar lipid vesicles, for example, "liposomes"-lamellar phase lipid bilayers, which in some embodiments are substantially spherical, and in more specific embodiments, can include an aqueous core, for example, including the substantial portion of an RNA molecule), an internal phase in a dispersed phase, micelle or suspension in an emulsion. Emulsions, micelles and suspensions can be suitable compositions for topical and / or external delivery.

[0034] Cationic lipids refer to lipid molecules capable of carrying a positive charge. In some embodiments, the cationic lipids may include at least one of ionizable cationic lipids and permanent cationic lipids. In some embodiments, the cationic lipids may include at least one of ionizable cationic lipids and permanent cationic lipids. In some embodiments, the molar ratio of the ionizable cationic lipid to the permanent cationic lipid may be 27.5-47.5:10-22.5. In some embodiments, the molar ratio of the ionizable cationic lipid to the permanent cationic lipid may be 30-45:10-20. In some embodiments, the molar ratio of the ionizable cationic lipid to the permanent cationic lipid may be 32.5-42.5:10-17.5. In some embodiments, the molar ratio of the ionizable cationic lipid to the permanent cationic lipid may be 35-40:10-15. In some embodiments, the molar ratio of the ionizable cationic lipid to the permanent cationic lipid may be 37.5-40:12.5-15.

[0035] In some embodiments, preferably, the molar ratio of the ionizable cationic lipid to the permanent cationic lipid may be 30-41.5:10-25. In some embodiments, more preferably, the molar ratio of the ionizable cationic lipid to the permanent cationic lipid may be 41-41.5:10.

[0036] Ionizable cationic lipids have a pH-sensitive ammonium head group with a pKa between 6.0 and 7.0. In a low pH environment, the polar head group of the lipid is positively charged and can bind to negatively charged gene drugs through electrostatic interaction. At pH 7.4, the lipid remains electrically neutral or electronegative, ensuring stability in serum. At the same time, it can avoid the degradation of gene drugs in endosomes or lysosomes with weakly acidic pH, thereby achieving endosomal / lysosomal escape; the ionizable cationic lipid also includes two long C18 carbon chains, and each carbon chain has two unsaturated double bonds, which significantly increases the hydrophobic area in this type of lipid, thereby promoting membrane fusion and facilitating the destruction of the bilayer membrane structure. In some embodiments, the ionizable cationic lipid may include any one of 1-octylnonyl 8-[(2-hydroxyethyl)[6-O-6-(undecanyloxy)hexyl]amino]-octanoate (SM102) or ((4-hydroxybutyl)azadialkyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315).

[0037] A permanent cationic lipid is a lipid that has a positive charge and does not change its charge with changes in solution pH. In some embodiments, the permanent cationic lipid can be (2,3-dioleoyl-propyl)-trimethylammonium chloride (DOTAP).

[0038] PEGylated lipids refer to molecules comprising a polyethylene glycol portion and a lipid portion. PEGylated lipids not only help control the particle size of lipid nanoparticles, but also help form a hydration layer on the outside of the particles, stabilize the charge on the surface of the particles, and avoid fusion between particles. They also play an important role in the preparation process and intracellular delivery. In some embodiments, the PEGylated lipids may include any one or more of 1,2-distearoyl-SN-glycerol-3-phosphoethanolamine-N-polyethylene glycol 2000-biotin (DSPE-PEG2000-Biotin), 1,2-dimyristoyl-rac-glycerol-3-methoxypolyethylene glycol 2000 (DMG-PEG2000), and 1,2-distearoyl-SN-glycerol-3-phosphoethanolamine-N-polyethylene glycol 2000-folic acid (DSPE-PEG2000-folic acid).

[0039] The present application also provides the use of the lipid nanoparticles as a delivery vehicle for nucleic acids.

[0040] In some embodiments, the nucleic acid can be a nucleic acid for gene editing.

[0041] The present application also provides a lipid nanoparticle-nucleic acid complex, which comprises a nucleic acid and the above-mentioned lipid nanoparticle, wherein the nucleic acid is loaded in the lipid nanoparticle.

[0042] In some embodiments, the molar ratio of the lipid nanoparticle to the nucleic acid can be 4 to 8. In some embodiments, the molar ratio of the lipid nanoparticle to the nucleic acid can be 5 to 7. In some embodiments, the molar ratio of the lipid nanoparticle to the nucleic acid is 6.

[0043] Nucleic acid refers to a polymer containing at least two deoxyribonucleotides or ribonucleotides in a single-stranded or double-stranded form, and includes DNA, RNA, and hybrids thereof. In some embodiments, the nucleic acid may include at least one of DNA or RNA.

[0044] In some embodiments, the RNA may include one or more of antisense RNA, saRNA, mRNA, lncRNA, miRNA, siRNA, piRNA, sgRNA, and tsRNA.

[0045] In some embodiments, the mRNA may include Cas9 nuclease mRNA or cytosine base editor mRNA. The sgRNA is a TIGIT gene sgRNA.

[0046] The sgRNA can guide the Cas nuclease to a target sequence on a target nucleic acid molecule, where the sgRNA hybridizes to the target sequence and the Cas nuclease cleaves or regulates the target sequence.

[0047] A base editor is an engineered gene editing tool created by fusing a deaminase to a programmable DNA-binding protein. It can achieve precise nucleotide changes at target genomic sites. Unlike cutting-type gene editing tools such as CRISPR-Cas9, base editors do not require double-strand breaks, thus offering unique advantages in safety and precision. Cytosine base editors (CBEs) can efficiently replace cytosine with thymine (C→T) at target sites without generating double-strand breaks.

[0048] In some embodiments, the mRNA may further comprise an mRNA of a reporter molecule. In some embodiments, the reporter molecule may include but is not limited to green fluorescent protein (GFP), blue fluorescent protein (BFP), enhanced GFP (EGFP), red fluorescent protein (RFP).

[0049] In some embodiments, the mass ratio of the mRNA to the sgRNA may be 1-5:1-5. In some embodiments, the mass ratio of the mRNA to the sgRNA may be 1-4:1-4. In some embodiments, the mass ratio of the mRNA to the sgRNA may be 1-3:1-3. In some embodiments, the mass ratio of the mRNA to the sgRNA may be 1-2:1-2. In some embodiments, the mass ratio of the mRNA to the sgRNA may be 1:1.

[0050] In some embodiments, preferably, the mass ratio of the mRNA to sgRNA can be 5:1.

[0051] The present application also provides the use of the above-mentioned lipid nanoparticle-nucleic acid complex for gene editing.

[0052] In some embodiments, the lipid nanoparticle-nucleic acid complex can have at least one of the following effects:

[0053] a. Improve nucleic acid transfection efficiency; b. Improve gene editing efficiency; c. Improve base editing efficiency.

[0054] The present application also provides use of the above-mentioned lipid nanoparticle-nucleic acid complex in the preparation of drugs for treating eye-related diseases.

[0055] In some embodiments, the eye-related disease may be an acquired retinal degenerative disease. In some embodiments, the acquired retinal degenerative disease may be age-related macular degeneration. In some embodiments, the age-related macular degeneration may include dry age-related macular degeneration and wet age-related macular degeneration. In some embodiments, the lipid nanoparticle-nucleic acid complex may be used for retinal pigment epithelial cell transfection, gene editing, or base editing.

[0056] The application also provides a method for delivering nucleic acid to a cell, comprising contacting the above-mentioned lipid nanoparticle-nucleic acid complex with a cell. In some embodiments, the cell can be a retinal pigment epithelial cell. In some embodiments, the cell can be an ARPE-19 cell. In some embodiments, the lipid nanoparticle-nucleic acid complex is contacted with an ARPE-19 cell or a 293T cell.

[0057] The present application also provides a gene editing method, comprising contacting the above-mentioned lipid nanoparticle-nucleic acid complex with a cell containing the gene to be edited. In some embodiments, the cell containing the gene to be edited can be a retinal pigment epithelial cell. In some embodiments, the cell containing the gene to be edited can be an ARPE-19 cell.

[0058] The present application also provides the use of DSPE-PEG-Biotin in preparing the above-mentioned lipid nanoparticles and the above-mentioned lipid nanoparticle-nucleic acid complexes.

[0059] The experimental methods in the following examples, unless otherwise specified, are all conventional methods. The experimental materials used in the following examples, unless otherwise specified, were purchased from conventional biochemical reagent companies. The quantitative experiments in the following examples were all repeated three times, and the results were averaged.

[0060] We previously tested the ability of LNPs prepared with the DLin-MC3-DMA cationic lipid to transfect ARPE-19 cells in vitro. Therefore, we designed 22 different protocols for testing ARPE19 cells. Four protocols were selected: Protocol 6, Protocol 10, Protocol 21, and Protocol 22 (see Figures 1-3).

[0061] The four schemes, Scheme 6, Scheme 11, Scheme 21 and Scheme 22, are different from conventional LNP components. Conventional LNP components are cholesterol, ionizable cationic lipids, auxiliary phospholipids, and PEGylated lipids. In the four schemes, the LNP components are cholesterol, ionizable cationic lipids, permanent cationic lipids, auxiliary phospholipids, and PEGylated lipids (or modified PEGylated lipids).

[0062] The contents encapsulated by the LNP are mRNA, sgRNA, siRNA, miRNA, ssDNA, plasmid or a mixture of these nucleic acid substances in any proportion.

[0063] In the following examples, Cas9 mRNA and sgRNA were prepared using existing technologies. Cas9 mRNA was purchased from Absin, catalog number abs60174. The sgRNA used was TIGIT sgRNA-3, described in Example 3 of patent WO2022CN93747. CE-CEB mRNA was transcribed from CE-CEB, described in Example 1 of patent 202010163058.3.

[0064] The following examples do not list all the 22 methods for preparing LNPs and LNP-RNA complexes and the methods for detecting transfection efficiency and editing efficiency. For the implementation of the remaining methods, refer to Examples 1-13.

[0065] Example 1: LNP Formula 1 of Green Fluorescent Protein EGFP mRNA

[0066] The nitrogen-to-phosphorus ratio is a parameter used in the preparation of LNPs containing nucleic acid. It determines the ratio of nucleic acid to lipid, typically expressed as a molar ratio. Nitrogen refers to the cationic lipid, while phosphorus refers to the phosphate groups in the nucleic acid. The nitrogen-to-phosphorus ratio is typically between 4 and 8.

[0067] The optimal nitrogen-phosphorus ratio is 6. All schemes in the present invention not otherwise specified have a nitrogen-phosphorus ratio of 6.

[0068] Taking mRNA as an example, in Scheme 6, 2 μg of green fluorescent protein (EGFP) mRNA is required. With a nitrogen-to-phosphorus ratio of 6, 17.802 nmol / μg of cationic lipid is required. The cationic lipid constitutes 51.5% of the total LNP lipids, resulting in a total lipid mass of 34.567 nmol / μg.

[0069] According to the ratio of the sixth protocol, cholesterol 9.890 μg, DSPC 5.463 μg, SM-102 20.375 μg, DOTAP 4.829 μg, and DMG-PEG 2.602 μg.

[0070] Example 2: LNP Formula 2 of Green Fluorescent Protein EGFP mRNA

[0071] Taking mRNA as an example, in Scheme 10, 2 μg of green fluorescent protein (EGFP) mRNA requires 17.802 nmol / μg of cationic lipid. Cationic lipids make up 51.5% of the total LNP lipids, resulting in a total lipid mass of 34.567 nmol / μg.

[0072] According to the component ratio of Scheme 10, β-sitosterol 10.608 μg, DSPC 5.463 μg, SM-102 20.375 μg, DOTAP 4.829 μg, and DMG-PEG 2.602 μg.

[0073] Example 3: LNP Formula 3 of Green Fluorescent Protein EGFP mRNA

[0074] Taking mRNA as an example, in Scheme 21, 2 μg of green fluorescent protein (EGFP) mRNA requires 17.802 nmol / μg of cationic lipid. Cationic lipids comprise 51.0% of the total LNP lipids, resulting in a total lipid mass of 34.906 nmol / μg.

[0075] According to the ratio of the protocol 21, cholesterol 9.987 μg, DSPC 5.516 μg, SM-102 20.327 μg, DOTAP 4.877 μg, DSPE-PEG-Biotin 3.840 μg.

[0076] Example 4: LNP Formula 4 of Green Fluorescent Protein EGFP mRNA

[0077] Taking mRNA as an example, in Scheme 22, 2 μg of green fluorescent protein (EGFP) mRNA requires 17.802 nmol / μg of cationic lipid. Cationic lipids comprise 51.5% of the total LNP lipids, resulting in a total lipid mass of 34.567 nmol / μg.

[0078] According to the ratio of the protocol 22, cholesterol 9.890 μg, DSPC 5.463 μg, ALC-0315 20.375 μg, DOTAP 4.829 μg, DMG-PEG 2.602 μg.

[0079] Example 5: LNP formulation 1 for the CRISPR-Cas9 system

[0080] The CRSPR-Cas9 system requires Cas9 protein mRNA and sgRNA in ratios ranging from 5:1, 2:1, 1:1, 1:2 to 1:5. The ratio of 5:1 is used in the present invention unless otherwise specified.

[0081] Taking 2.5 μg of mRNA and 0.5 μg of sgRNA as an example, in Scheme 6, 3 μg of RNA for the CRSPR-Cas9 system is required. The required cationic lipid mass is 17.802 nmol / μg. The cationic lipid accounts for 51.5% of the total LNP lipids, for a total lipid mass of 34.567 nmol / μg.

[0082] According to the ratio of the sixth scheme, cholesterol 14.836 μg, DSPC 8.194 μg, SM-102 30.563 μg, DOTAP 7.244 μg, DMG-PEG 3.903 μg.

[0083] Example 6: LNP Formulation 2 for CRISPR-Cas9 System

[0084] Taking 2.5 μg of mRNA and 0.5 μg of sgRNA as an example, in Scheme 10, 3 μg of RNA for the CRSPR-Cas9 system is required. The required cationic lipid mass is 17.802 nmol / μg. The cationic lipid accounts for 51.5% of the total LNP lipids, for a total lipid mass of 34.567 nmol / μg.

[0085] According to the ratio of the protocol, cholesterol 14.836 μg, DSPC 8.194 μg, SM-102 30.563 μg, DOTAP 7.244 μg, DMG-PEG 3.903 μg.

[0086] Example 7: LNP Formulation 3 for CRISPR-Cas9 System

[0087] Taking Scheme 21 as an example, using 2.5 μg of mRNA and 0.5 μg of sgRNA as the nucleic acid material, 3 μg of RNA for the CRSPR-Cas9 system requires 17.802 nmol / μg of cationic lipid. Cationic lipids comprise 51.0% of the total LNP lipids, for a total lipid mass of 34.906 nmol / μg.

[0088] According to the ratio of the protocol 21, cholesterol 14.981 μg, DSPC 8.274 μg, SM-102 30.491 μg, DOTAP 7.315 μg, DSPE-PEG-Biotin 5.759 μg.

[0089] Example 8: LNP Formulation 4 for CRISPR-Cas9 System

[0090] Taking 2.5 μg of mRNA and 0.5 μg of sgRNA as an example, in Scheme 22, 3 μg of RNA for the CRSPR-Cas9 system requires 17.802 nmol / μg of cationic lipid. Cationic lipids comprise 51.5% of the total LNP lipids, for a total lipid mass of 34.567 nmol / μg.

[0091] According to the ratio of the protocol 22, cholesterol 14.836 μg, DSPC 8.194 μg, ALC-0315 32.977 μg, DOTAP 7.244 μg, DMG-PEG 3.903 μg.

[0092] The formulation is not limited to EGFP and CRISPR-Cas9 mRNA, and the ratio of mRNA:sgRNA (w / w) is 5:1.

[0093] Example 9: Preparation Method 1 of Laboratory-Grade Micro-LNP-RNA Complex

[0094] 1. Prepare 2.5μl, 20μl, 200μl, and 1000μl pipettes, 10, 200, and 1000μl sterile pipette tips without nuclease, 0.6ml centrifuge tubes, 8-strip PCR tubes, 15ml centrifuge tubes, 50ml centrifuge tubes, 15ml 100KDa ultrafiltration centrifuge tubes, DEPC water, 20XPBS, sodium citrate buffer (50mmol, pH=4), nuclease scavenger, 75% alcohol, anhydrous ethanol, 8-strip PCR tube rack, 1.5ml centrifuge tube rack, 15 / 50ml centrifuge tube rack, 50ml syringe, and 0.22μm needle filter (the liquids, tubes, etc. mentioned above are all sterile without nuclease).

[0095] 2. Prepare the working solutions of cholesterol, DSPC, SM-102, DOTAP, and DMG-PEG2000 with anhydrous ethanol in advance. The concentration of each working solution is 2 mg / ml. Seal and store in the refrigerator to prevent ethanol volatilization from affecting the concentration.

[0096] 3. Disinfect with 75% alcohol, then treat the operating environment with a nuclease remover to create a sterile and nuclease-free environment (clean bench).

[0097] 4. Prepare 1xPBS with 20xPBS and DEPC water, then filter it into a 50ml centrifuge tube with a syringe for later use, and then divide 6ml of PBS into 15ml centrifuge tubes.

[0098] 5. Pipette cholesterol, DSPC, SM-102, DOTAP, and DMG-PEG in the amounts described in Example 1 and mix them into one well of the 8-well PCR tube strip; then take another 148 μl of sodium citrate buffer and add it to another well, and then add 2 μg of EGFP mRNA and mix well.

[0099] 6. Add anhydrous ethanol to the organic phase of the lipids to a volume of 50 μl and mix thoroughly. Use two pipettes (using both hands) to draw 50 μl of the organic phase and 150 μl of the aqueous phase, respectively, and quickly add them to a 0.6 ml centrifuge tube at the same time. Place in a vortex mixer (2000 rpm, 10 minutes).

[0100] 7. Add equal volume (200 μl for the organic phase and aqueous phase in total) of PBS solution (prepared in step 4) and place in a vortex mixer (2000 rpm, 10 min).

[0101] 8. Add the mixed liquid in step 7 to the 15ml centrifuge tube in step 4.

[0102] 9. Concentrate the LNP-mRNA mixed solution using an ultrafiltration centrifuge tube (3000 rpm, 5 min). After concentration is complete, add 2 ml of PBS prepared in step 4 and centrifuge to wash the LNP three times.

[0103] 10. Transfer the concentrated LNP into eight PCR tubes, with a total volume of 50-100 μl, and store at 2-4 degrees.

[0104] Example 10: Preparation Method 2 of Laboratory-Grade Micro-LNP-RNA Complex

[0105] 1. Prepare 2.5μl, 20μl, 200μl, and 1000μl pipettes, 10, 200, and 1000μl sterile pipette tips without nuclease, 0.6ml centrifuge tubes, 8-strip PCR tubes, 15ml centrifuge tubes, 50ml centrifuge tubes, 15ml 100KDa ultrafiltration centrifuge tubes, DEPC water, 20XPBS, sodium citrate buffer (50mmol, pH=4), nuclease scavenger, 75% alcohol, anhydrous ethanol, 8-strip PCR tube rack, 1.5ml centrifuge tube rack, 15 / 50ml centrifuge tube rack, 50ml syringe, and 0.22μm needle filter (the liquids, tubes, etc. mentioned above are all sterile without nuclease).

[0106] 2. Prepare the working solutions of cholesterol, DSPC, SM-102, DOTAP, and DMG-PEG2000 with anhydrous ethanol in advance. The concentration of the working solutions is 2 mg / ml. Seal and store in the refrigerator to prevent ethanol volatilization from affecting the concentration.

[0107] 3. Disinfect with 75% alcohol, then treat the operating environment with a nuclease remover to create a sterile and nuclease-free environment (clean bench).

[0108] 4. Prepare 1xPBS with 20xPBS and DEPC water, then filter it into a 50ml centrifuge tube with a syringe for later use, and then divide 6ml of PBS into 15ml centrifuge tubes.

[0109] 5. Pipette cholesterol, DSPC, SM-102, DOTAP, and DMG-PEG in the amounts described in Example 1 and mix them in one well of the 8-well PCR tube; then take another 147 μl of sodium citrate buffer and add it to another well, then add 2.5 μg of Cas9 mRNA and 0.5 μg of sgRNA, and incubate for 2 min.

[0110] 6. Add anhydrous ethanol to the organic phase of the lipids to a volume of 50 μl and mix thoroughly. Use two pipettes (using both hands) to draw 50 μl of the organic phase and 150 μl of the aqueous phase, respectively, and quickly add them to a 0.6 ml centrifuge tube at the same time. Place in a vortex mixer (2000 rpm, 10 minutes).

[0111] 7. Add equal volume (200 μl for the organic phase and aqueous phase in total) of PBS solution (prepared in step 4) and place in a vortex mixer (2000 rpm, 10 min).

[0112] 8. Add the mixed liquid in step 7 to the 15ml centrifuge tube in step 4.

[0113] 9. Use an ultrafiltration centrifuge tube to concentrate the LNP-mRNA mixed solution (3000 rpm, 5 min). After concentration is complete, add 2 ml of PBS prepared in step 4 and centrifuge to wash the LNP three times.

[0114] 10. Transfer the concentrated LNP into eight PCR tubes, with a total volume of 50-100 μl, and store at 2-4 degrees.

[0115] Example 11: Delivery of nucleic acids to ARPE-19 cells by LNP-RNA complexes

[0116] 293T cells and ARPE-19 cells were inoculated and cultured in 24-well plates in DMEM high-glucose medium (HyClone, SH30022.01B) supplemented with 10% FBS, with 1×10 cells per well. 5 Cells were grown in a 500 μg / ml culture medium containing penicillin (100 U / ml) and streptomycin (100 μg / ml). Two hours before transfection, the culture medium was changed to antibiotic-free medium. 100 μl of the LNP-RNA complex prepared in Example 9 (equivalent to 1 μg of EGFP mRNA) was then added to each well and cultured for 24-48 hours. Fluorescence analysis of the cells was performed by flow cytometry to determine the transfection efficiency of the LNP-RNA complex. The results are shown in Figures 4-5.

[0117] Example 12: LNP-RNA complex delivery of CE-CBE mRNA to ARPE-19 cells

[0118] 293T cells and ARPE-19 cells were inoculated and cultured in 24-well plates in DMEM high-glucose medium (HyClone, SH30022.01B) supplemented with 10% FBS, with 1×10 cells per well. 5 cells, containing penicillin (100 U / ml) and streptomycin (100 μg / ml). Two hours before transfection, the medium was changed to antibiotic-free medium. Then, 100 μl of the LNP-RNA complex prepared by Example 10 (equivalent to 1.25 μg CE-CBE mRNA and 0.25 μg sgRNA) was added to each well and cultured for 48 hours. The cells were then lysed and PCR amplified using appropriate primers. Finally, the PCR amplification products were subjected to Sanger sequencing to analyze the base editing efficiency, and the results are shown in Figure 6.

[0119] Example 13: LNP-RNA complex delivery of Cas9 mRNA to ARPE-19 cells

[0120] ARPE-19 cells were inoculated and cultured in 24-well plates in DMEM high-glucose medium (HyClone, SH30022.01B) supplemented with 10% FBS, with 1×10 cells per well. 5 cells, containing penicillin (100 U / ml) and streptomycin (100 μg / ml). Two hours before transfection, the medium was changed to antibiotic-free medium. Then, 100 μl of the LNP-RNA complex prepared by Example 10 (equivalent to 1.25 μg Cas9 mRNA and 0.25 μg sgRNA) was added to each well and cultured for 48 hours. The cells were then lysed and PCR amplification was performed using appropriate primers. Finally, the PCR amplification products were subjected to Sanger sequencing to analyze the gene editing efficiency, and the results are shown in Figure 7.

[0121] Preferred Schemes 6, 10, 21, and 22 of the present application prepare corresponding LNP-RNA complexes of EGFP mRNA using the method of Example 9, and conduct in vitro cell experiments using the method of Example 11 to detect the transfection efficiency of the LNP-RNA complexes (see Figures 4-5). The four preferred schemes have a delivery efficiency of nearly 100% for EGFP mRNA. This indicates that Schemes 6, 10, 21, and 22 all have a gene delivery efficiency close to 100%.

[0122] Preferred Schemes 6, 10, 21, and 22 of the present application prepare the corresponding LNP-RNA complex of CECBE mRNA by the method of Example 10, and conduct in vitro cell experiments by the method of Example 12, detecting that the base editing efficiency of the LNP-RNA complex reaches 56% (see Figure 6).

[0123] Preferred Schemes 6, 10, 21, and 22 of the present application prepare the corresponding Cas9mRNA LNP-RNA complex by the method of Example 10, and conduct in vitro cell experiments by the method of Example 13, detecting that the gene editing efficiency of the LNP-RNA complex reaches 78% (see Figure 7).

[0124] While the basic concepts have been described above, it will be apparent to those skilled in the art that the detailed disclosure is merely illustrative and does not limit this specification. Although not explicitly stated herein, various modifications, improvements, and revisions to this specification may be made by those skilled in the art. Such modifications, improvements, and revisions are suggested in this specification and remain within the spirit and scope of the exemplary embodiments of this specification.

[0125] This specification also uses specific terms to describe the embodiments of this specification. For example, "one embodiment," "an embodiment," and / or "some embodiments" refer to a feature, structure, or characteristic associated with at least one embodiment of this specification. Therefore, it should be emphasized and noted that references to "one embodiment," "an embodiment," or "an alternative embodiment" two or more times in different locations in this specification do not necessarily refer to the same embodiment. Furthermore, certain features, structures, or characteristics of one or more embodiments of this specification may be appropriately combined.

[0126] In some embodiments, numbers are used to describe the quantity of components and attributes. It should be understood that such numbers used in the description of the embodiments are modified by the modifiers "about", "approximately" or "substantially" in some examples. Unless otherwise stated, "about", "approximately" or "substantially" indicate that the numbers are allowed to vary by ±20%. Accordingly, in some embodiments, the numerical parameters used in the description and claims are approximate values, which may change according to the required characteristics of individual embodiments. In some embodiments, the numerical parameters should take into account the specified significant digits and adopt the general method of retaining digits. Although the numerical domains and parameters used to confirm the breadth of their range in some embodiments of this specification are approximate values, in specific embodiments, the settings of such numerical values ​​are as accurate as possible within the feasible range.

[0127] Finally, it should be understood that the embodiments described in this specification are intended only to illustrate the principles of the embodiments of this specification. Other variations may also fall within the scope of this specification. Therefore, by way of example and not limitation, alternative configurations of the embodiments of this specification may be considered consistent with the teachings of this specification. Accordingly, the embodiments of this specification are not limited to the embodiments explicitly described and illustrated in this specification.

Claims

1. A lipid nanoparticle suitable for RPE cell transfection, characterized in that: The raw materials of the lipid nanoparticles include steroidal lipids, cationic lipids, auxiliary lipids and PEGylated lipids, and the molar ratio of the steroidal lipids, auxiliary lipids, cationic lipids and PEGylated lipids is 37:10:51-51.5:1.5-2; the steroidal lipids are selected from at least one of cholesterol or β-sitosterol, the auxiliary lipids are selected from at least one of cardiolipin or DSPC, the cationic lipids are selected from at least two of SM102, DOTAP or ALC-0315, the PEGylated lipids are selected from at least one of DSPE-PEG-Biotin, DMG-PEG or PEG-folic acid, the cationic lipids include ionizable cationic lipids and permanent cationic lipids, and the molar ratio of the ionizable cationic lipids to the permanent cationic lipids is 25-50:10-25.

2. The lipid nanoparticle according to claim 1, characterized in that The molar ratio of the ionizable cationic lipid to the permanent cationic lipid is 30-41.5:10-25.

3. The lipid nanoparticle according to claim 1, characterized in that The molar ratio of the ionizable cationic lipid to the permanent cationic lipid is 41-41.5:

10.

4. Use of the lipid nanoparticles according to any one of claims 1 to 3 as a delivery vector for nucleic acids.

5. The use according to claim 4, characterized in that The nucleic acid is a nucleic acid for gene editing.

6. A lipid nanoparticle-nucleic acid complex, characterized in that: The lipid nanoparticle-nucleic acid complex comprises a nucleic acid and the lipid nanoparticle according to any one of claims 1 to 3, wherein the nucleic acid is loaded in the lipid nanoparticle.

7. The lipid nanoparticle-nucleic acid complex according to claim 6, characterized in that The molar ratio of the lipid nanoparticles to the nucleic acid is 4 to 8; And / or, the nucleic acid comprises at least one of DNA or RNA.

8. The lipid nanoparticle-nucleic acid complex according to claim 6, characterized in that The molar ratio of the lipid nanoparticles to the nucleic acid is 6.

9. The lipid nanoparticle-nucleic acid complex according to claim 7, characterized in that: The RNA includes one or more of antisense RNA, saRNA, mRNA, lncRNA, miRNA, siRNA, piRNA, sgRNA, and tsRNA.

10. The lipid nanoparticle-nucleic acid complex according to claim 9, characterized in that The mRNA includes Cas9 nuclease mRNA or cytosine base editor mRNA, and the sgRNA is TIGIT gene sgRNA.

11. The lipid nanoparticle-nucleic acid complex according to claim 9, characterized in that: The mRNA also includes the mRNA of a reporter molecule.

12. The lipid nanoparticle-nucleic acid complex according to claim 9 or 10, characterized in that: The mass ratio of the mRNA to the sgRNA is 1-5:1-5.

13. The lipid nanoparticle-nucleic acid complex according to claim 9 or 10, characterized in that: The mass ratio of the mRNA to sgRNA is 5:

1.

14. Use of the lipid nanoparticle-nucleic acid complex according to any one of claims 6 to 13 for gene editing.

15. The use according to claim 14, characterized in that The lipid nanoparticle-nucleic acid complex has at least one of the following effects: a. Improve nucleic acid transfection rate; b. Improve the efficiency of gene editing; c Improve base editing efficiency.

16. Use of the lipid nanoparticle-nucleic acid complex according to any one of claims 6 to 13 in the preparation of drugs for treating eye-related diseases.

17. The use according to claim 16, characterized in that The eye-related disease is an acquired retinal degenerative disease, the acquired retinal degenerative disease is an age-related macular degeneration disease, the age-related macular degeneration disease includes dry age-related macular degeneration disease and wet age-related macular degeneration disease, and the lipid nanoparticle-nucleic acid complex is used for retinal pigment epithelial cell transfection, gene editing, and base editing.

18. A method for delivering a nucleic acid to a cell, comprising contacting the lipid nanoparticle-nucleic acid complex according to any one of claims 6 to 13 with a cell.

19. A gene editing method, comprising contacting the lipid nanoparticle-nucleic acid complex described in any one of claims 6 to 13 with a cell containing a gene to be edited.

20. Use of DSPE-PEG-Biotin in the preparation of the lipid nanoparticles according to any one of claims 1 to 3 and the lipid nanoparticle-nucleic acid complexes according to any one of claims 6 to 13.

Citation Information

Patent Citations

  • Compositions and methods for organ specific delivery of nucleic acids

    CN112996519A

  • Polyethylene glycol lipid and application thereof

    CN114276535A

  • Ionizable lipid nanoparticles and uses thereof

    CN114617980A

  • Encapsulated oncolytic virus genetic material and use thereof

    CN115227674A

  • Lipid nanoparticle suitable for RPE cell transfection and application thereof

    CN116271105A